P483: QUANTUM-FIRST TRIAL: FLT3-ITD–SPECIFIC MEASURABLE RESIDUAL DISEASE (MRD) CLEARANCE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVALMark J. Levis, Alexander E. Perl, Elżbieta Patkowska et al.|HemaSphere|2023Cited by 3
S137: IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN FIRST COMPLETE REMISSION PLUS FLT3 INHIBITION WITH QUIZARTINIB IN ACUTE MYELOID LEUKEMIA WITH FLT3-ITD: RESULTS FROM QUANTUM-FIRSTRichard F. Schlenk, Harry P. Erba, Pau Montesinos et al.|HemaSphere|2023Cited by 0